EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Genetic Polymorphisms in Apoptosis-Related Genes XAF1 and XIAP Are Associated with Clinical Outcomes in Pediatric Ewing Sarcoma

Leonardo Vinícius Barbosa, Ana Clara de Almeida, Cui Tu, Rafael Roesler, Caroline Brunetto de Farias, Roberto Rosati, Luciane Regina Cavalli, Arutha Kulasinghe, Fernando Souza-Fonseca Guimarães, Lucia de Noronha, Cleber Machado-Souza

Diagnostics · 2026-11-12 · 16 (22) · 3751

DOI: 10.3390/diagnostics16223751 ↗
AbstractBibliografische Angaben

Abstract

Background/Objectives: Ewing sarcoma (ES) is an aggressive malignant cancer with a higher incidence in adolescents and young adults. Despite multimodal therapy, prognosis remains poor, particularly in metastatic and recurrence cases. Dysregulation of apoptosis is central to ES tumorigenesis; however, the impact of polymorphisms in apoptotic regulators on clinical outcomes remains unclear. This study investigated the association between single-nucleotide polymorphisms (SNPs) in the apoptotic pathway genes XAF1 and XIAP and their respective protein expression in ES outcomes. Methods: A cross-sectional study was conducted on ES samples from paraffin blocks (n = 55). Genotyping for selected SNPs and immunohistochemistry for XAF1 and XIAP expression were performed. The cohort included 41 pediatric and 14 non-pediatric cases. Statistical associations were analyzed between genotypes, age groups, protein expression, and recurrence. Results: The male sex (61.8%) and bone site (75.5%) were prevalent, while recurrence (30.9%) and metastasis (14.5%) were frequent outcomes. There was low or absent XAF1 expression (

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →